Although breast cancers that overexpress human epidermal growth factor receptor-2 (HER2) are characterized by a poor prognosis [4,5], higher rates of complete responses are currently achieved in HER2+ patients by standard chemotherapy, mainly in association with trastuzumab [6,7], in comparison with HER2- patients.